Chronic Idiopathic Constipation (CIC) Drugs Market Analysis & Forecast 2024-2030

Global Chronic Idiopathic Constipation (CIC) Drugs Market is expected to reach USD 7972.12 million by 2030 with CAGR of 7.1% between 2024 and 2030

Global Chronic Idiopathic Constipation (CIC) Drugs Market is estimated to grow at a CAGR of 6.6% between 2024 and 2030.If the constipation happens chronically with an unidentifiable cause it is known as Chronic Idiopathic Constipation (CIC). The word "Idiopathic" means the cause is not known. Increasing awareness and widespread presence of idiopathic constipation are the key factors for growth of CIC drugs market. Currently CIC drugs market has huge opportunity for research and development.  

Depending on type of drugs, global CIC drugs market is segmented into Lubiprostone, Linaclotide and others. Currently Lubiprostone drug segment dominates the market. But, due to its lower efficacy in comparison with others, patent loss and growing competition from Linaclotide, Lubiprostone will lose its dominance in the upcoming future. Depending on prescription types it is subdivided into prescribed drugs and over the counter drugs. After analysing the symptoms also, constipation is not considered as a disease but a condition, side effect or syndrome.  

Usually patients avoid to visit doctors to address the issue. Therefore approximately 65% of the CIC drugs market is covered by over the counter drugs. The top players of CIC drugs market are Actavis, Chugai Pharmaceutical, Ferring International Center S.A., Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding AG, Sanofi, Bayer AG, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc, Ironwood Pharmaceuticals and Progenics Pharmaceuticals.  

Geographically, Global Chronic Idiopathic Constipation (CIC) Drugs Market is divided into several regions such as North America, Europe, China, Japan, Southeast Asia and India. In upcoming years, North America is expected to dominate the CIC drug market. In North America approximately 28% of population suffers from chronic idiopathic constipation.  

Also Government in this region is taking steps to medicate and to develop the healthcare sectors by providing advance technological and developed medication treatments support. These are major factors for growth of CIC market in North America. It is anticipated that growing awareness in developing Asian countries like China and India will create significant growth in the Asia Pacific market.  

Chronic Idiopathic Constipation (CIC) Drugs Market: Product Type

• Lubiprostone
• Linaclotide

Chronic Idiopathic Constipation (CIC) Drugs Market: End Users/Application Analysis

• Hospitals & Clinics
• Ambulatory Surgical Centres
• Long Term Care Centres

Chronic Idiopathic Constipation (CIC) Drugs Market : Competitive Analysis

Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Chronic Idiopathic Constipation (CIC) Drugs Market :

• Actavis
• Chugai Pharmaceutical
• Ferring International Center S.A.
• Synergy Pharmaceuticals
• Pfizer
• GlaxoSmithKline
• Roche Holding AG
• Sanofi
• Bayer AG
• Salix Pharmaceuticals Ltd
• Sucampo Pharmaceuticals Inc
• Ironwood Pharmaceuticals
• Progenics Pharmaceuticals

Geographical analysis of Chronic Idiopathic Constipation (CIC) Drugs Market:

• North America
  • U.S.A
  • Canada
• Europe
  • France
  • Germany
  • Spain
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South East Asia
• Latin America
  • Brazil
• Middle East and Africa

Global Chronic Idiopathic Constipation (CIC) Drugs Market Report delivers a comprehensive analysis of the following parameters:

• Market Forecast for 2024-2030
• Market growth drivers
• Challenges and Opportunities
• Emerging and Current market trends
• Market player Capacity, Production, Revenue (Value)
• Supply (Production), Consumption, Export, Import analysis
• End user/application Analysis

---

Frequently Asked Questions (FAQ)